Related Experiment Video

Updated: Aug 2, 2026

Quantitative Immunoblotting of Cell Lines as a Standard to Validate Immunofluorescence for Quantifying Biomarker Proteins in Routine Tissue Samples
09:58

Quantitative Immunoblotting of Cell Lines as a Standard to Validate Immunofluorescence for Quantifying Biomarker Proteins in Routine Tissue Samples

Published on: January 7, 2019

Antisense oligonucleotides complementary to immunoglobulin sequences of BCL-2/immunoglobulin fusion transcript induce

M R Smith1, T Xie, Z Z Zhou

  • 1Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. m_smith@fccc.edu

British Journal of Haematology
|February 13, 2001
PubMed

Insights

Researchers targeted immunoglobulin sequences to downregulate bcl-2 in lymphoma cells. This approach inhibits cancer cell growth and offers potential for tumor-specific genetic manipulation.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetic Engineering

Background:

  • The t(14;18) translocation leads to aberrant bcl-2 expression in certain lymphomas.
  • Targeting the bcl-2 translational start site can inhibit lymphoma growth but may cause toxicity in normal cells.
  • The fusion transcript in t(14;18) lymphomas includes immunoglobulin sequences.

Purpose of the Study:

  • To investigate the efficacy of targeting immunoglobulin sequences within the bcl-2 fusion transcript.
  • To determine if this targeted approach can specifically downregulate bcl-2 and induce apoptosis in lymphoma cells.
  • To explore a novel strategy for tumor-specific genetic manipulation.

Main Methods:

  • Antisense oligodeoxyribonucleotides (ASOs) were designed to target immunoglobulin c(mu) sequences.
  • WSU-FSCCL cells, a t(14;18)-positive lymphoma line, were treated with the ASOs.
  • bcl-2 protein expression levels and apoptosis induction were assessed.

Main Results:

  • ASOs targeting immunoglobulin c(mu) sequences successfully downregulated bcl-2 protein expression.
  • This downregulation led to apoptosis in WSU-FSCCL cells.
  • The study demonstrated successful inhibition of malignant cell growth.

Conclusions:

  • Targeting non-oncogenic immunoglobulin sequences in the fusion transcript is a viable strategy for bcl-2 downregulation.
  • This approach offers potential for tumor-specific genetic manipulation with reduced toxicity to normal cells.
  • Antisense technology targeting fusion gene non-oncogenic sequences expands therapeutic possibilities in oncology.

More Related Videos

Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells09:57

Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells

Published on: January 29, 2019

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.